Aspira Women'S Health INC. 8-K/A Filing
Ticker: AWHL · Form: 8-K/A · Filed: Nov 3, 2025 · CIK: 926617
Sentiment: neutral
Filing Stats: 472 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-11-03 16:16:36
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 AWHL OTC QX Market Indicate by ch
Filing Documents
- awhl-20250919x8ka.htm (8-K/A) — 38KB
- awhl-20250919xex4d1.htm (EX-4.1) — 131KB
- 0001104659-25-105561.txt ( ) — 306KB
- awhl-20250919.xsd (EX-101.SCH) — 3KB
- awhl-20250919_lab.xml (EX-101.LAB) — 16KB
- awhl-20250919_pre.xml (EX-101.PRE) — 10KB
- awhl-20250919x8ka_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. Explanatory Note On September 25, 2025, Aspira Women's Health Inc. (the "Company") disclosed that it had entered into certain amendments to its Amended and Restated Series A Common Stock Warrants. The form of such warrant included with the original Form 8-K disclosure inadvertently included an incorrect termination date. The correct form of warrant is attached hereto as Exhibit 4.1 and incorporated herein by reference.
02 Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities. The information in Item 1.01 is hereby incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 4.1 Form of Amended and Restated Warrant 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Dated: November 3, 2025 ASPIRA WOMEN'S HEALTH INC. By: /s/ Michael Buhle Name: Michael Buhle Title: Chief Executive Officer